Kamran Alam

CIK: 0001793412

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TSHA

Taysha Gene Therapies, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TSHA
Taysha Gene Therapies, Inc.
Feb 4, 2026
Sale(S)
Direct
1.7K shares at avg. $4.52$7K
TSHA
Taysha Gene Therapies, Inc.
Jan 26, 2026
Sale(S)
Direct
23.8K shares at avg. $4.61$110K
TSHA
Taysha Gene Therapies, Inc.
Jan 23, 2026
Sale(S)
Direct
79K shares at avg. $4.75$375K
TSHA
Taysha Gene Therapies, Inc.
Jan 12, 2026
Award(A)
Direct
359K shares-
TSHA
Taysha Gene Therapies, Inc.
Aug 21, 2025
Sale(S)
Direct
54.5K shares at avg. $2.85$155K
TSHA
Taysha Gene Therapies, Inc.
Mar 11, 2025
Tax Payment(F)
Direct
29.8K shares at avg. $1.69$50K
TSHA
Taysha Gene Therapies, Inc.
Jan 2, 2025
Award(A)
Direct
431K shares-
TSHA
Taysha Gene Therapies, Inc.
May 31, 2023
Award(A)
Employee Stock Option (right to buy)
Direct
12.5K shares-

		Type	Shares	Price		Ownership
Feb 4, 2026	TSHA Taysha Gene Therapies, Inc.	Sale(S)	1,655	$4.52	$7,481	Direct
Jan 26, 2026	TSHA Taysha Gene Therapies, Inc.	Sale(S)	23,849	$4.61	$109,944	Direct
Jan 23, 2026	TSHA Taysha Gene Therapies, Inc.	Sale(S)	78,968	$4.75	$375,098	Direct
Jan 12, 2026	TSHA Taysha Gene Therapies, Inc.	Award(A)	359,000	-	$0	Direct
Aug 21, 2025	TSHA Taysha Gene Therapies, Inc.	Sale(S)	54,491	$2.85	$155,299	Direct
Mar 11, 2025	TSHA Taysha Gene Therapies, Inc.	Tax Payment(F)	29,843	$1.69	$50,435	Direct
Jan 2, 2025	TSHA Taysha Gene Therapies, Inc.	Award(A)	431,000	-	$0	Direct
May 31, 2023	TSHA Taysha Gene Therapies, Inc.	Award(A) Employee Stock Option (right to buy)	12,462	-	-	Direct

1-8 of 8 transactions

About Alam Kamran

Alam Kamran (SEC CIK 0001793412) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Taysha Gene Therapies, Inc. (TSHA).

Signal8 holds 7 ownership filings by Alam Kamran, all Form 4s, filed between Jan 3, 2025 and Feb 6, 2026. Those filings report 8 transactions, from May 31, 2023 to Feb 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Alam Kamran's filings is in DALLAS, TX.

Recent filings by Alam Kamran

Feb 4, 2026: Open-market sale of TSHA shares (Form 4, code S).
Jan 26, 2026: Open-market sale of TSHA shares (Form 4, code S).
Jan 23, 2026: Open-market sale of TSHA shares (Form 4, code S).
Jan 12, 2026: Grant or award of TSHA shares (Form 4, code A).
Aug 21, 2025: Open-market sale of TSHA shares (Form 4, code S).

Other insiders filing for Taysha Gene Therapies, Inc. (TSHA)

Nagendran Sukumar, President and Head of R&D
Stalfort John A III, Director
Donenberg Phillip B., Director
Long Alison S, Director
Sepp-Lorenzino Laura, Director
Nolan Sean P., Chief Executive Officer

How to read Form 4 transaction codes